My watch list  


Systematic (IUPAC) name
CAS number 60719-84-8
ATC code C01CE01
PubChem 3698
Chemical data
Formula C10H9N3O 
Mol. mass 187.198 g/mol
Pharmacokinetic data
Bioavailability n/a
Protein binding 10 to 49%
Metabolism Hepatic
Half life 5 to 8 hours
Excretion Renal (63%) and fecal (18%)
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Intravenous

Amrinone (INN) or inamrinone, trade name Inocor, is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

Class: Cardiac inotrope.
Actions: Increases cardiac contractility, vasodilator.
Indications: Short-term management of severe CHF.
Contraindications: Patients with history of hypersensitivity to the drug.
Precautions: May increase myocardial ischemia. Blood pressure, pulse, and EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone.
Side Effects: Reduction in platelets, nausea and vomiting cardiac arrhythmias.
Dosage: 0.75 mg/kg bolus given slowly over 2-3 minute interval followed by maintenance infusion of 2-15 µg/kg/minute.
Routes: IV bolus and infusion as described earlier.
Pediatric Dosage: Safety in children has not been established

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amrinone". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE